{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+checkpoint+inhibitor&page=3",
    "query": {
      "intervention": "Immune checkpoint inhibitor",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 371,
    "total_pages": 38,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+checkpoint+inhibitor&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+checkpoint+inhibitor&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T19:47:21.490Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07631325",
      "title": "Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Unresectable Cutaneous Melanoma"
      ],
      "interventions": [
        {
          "name": "Axelopran",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "John Kirkwood",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2026-11-30",
      "completion_date": "2030-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-18T19:47:21.490Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07631325"
    },
    {
      "nct_id": "NCT04214418",
      "title": "Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Gastrointestinal Cancer"
      ],
      "interventions": [
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2020-02-12",
      "completion_date": "2022-07-01",
      "has_results": true,
      "last_update_posted_date": "2024-12-18",
      "last_synced_at": "2026-11-18T19:47:21.490Z",
      "location_count": 2,
      "location_summary": "New York, New York • Providence, Rhode Island",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04214418"
    },
    {
      "nct_id": "NCT07404332",
      "title": "5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Locally Advanced Solid Tumor",
        "Metastatic Tumor"
      ],
      "interventions": [
        {
          "name": "5 Azacytidine",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mohammed Milhem",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 35,
      "start_date": "2026-02-11",
      "completion_date": "2031-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-11-18T19:47:21.490Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07404332"
    },
    {
      "nct_id": "NCT05933265",
      "title": "Study of LP-184 in Patients With Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Solid Tumor",
        "GBM",
        "TNBC - Triple-Negative Breast Cancer",
        "NSCLC",
        "Pancreatic Adenocarcinoma",
        "DDR Gene Mutation"
      ],
      "interventions": [
        {
          "name": "LP-184",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab & Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lantern Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2023-06-09",
      "completion_date": "2026-07-28",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-11-18T19:47:21.490Z",
      "location_count": 7,
      "location_summary": "Springdale, Arkansas • Indianapolis, Indiana • Louisville, Kentucky + 4 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05933265"
    },
    {
      "nct_id": "NCT06819735",
      "title": "Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "DT-7012",
          "type": "DRUG"
        },
        {
          "name": "Immune checkpoint inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Domain Therapeutics Australia Pty Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2025-06-25",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-11-18T19:47:21.490Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06819735"
    },
    {
      "nct_id": "NCT04508725",
      "title": "Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Kidney Cancer",
        "Renal Cell Carcinoma",
        "Metastatic Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Doppler Ultrasound",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "SIEMENS S3000 and Verasonics Vantage 256",
          "type": "DEVICE"
        },
        {
          "name": "Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)",
          "type": "DRUG"
        },
        {
          "name": "Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2020-12-05",
      "completion_date": "2023-11-30",
      "has_results": true,
      "last_update_posted_date": "2025-07-25",
      "last_synced_at": "2026-11-18T19:47:21.490Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04508725"
    },
    {
      "nct_id": "NCT05332925",
      "title": "Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lung Cancer",
        "NSCLC",
        "NSCLC Stage IV"
      ],
      "interventions": [
        {
          "name": "Standard of care immune checkpoint inhbitors",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jun Zhang, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 25,
      "start_date": "2022-07-21",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2024-02-23",
      "last_synced_at": "2026-11-18T19:47:21.490Z",
      "location_count": 2,
      "location_summary": "Fairway, Kansas • Kansas City, Kansas",
      "locations": [
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05332925"
    },
    {
      "nct_id": "NCT04681131",
      "title": "CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small-Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "CAB-AXL-ADC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PD-1 inhibitor",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BioAtla, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2021-03-17",
      "completion_date": "2025-07-09",
      "has_results": false,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-11-18T19:47:21.490Z",
      "location_count": 32,
      "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 26 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04681131"
    },
    {
      "nct_id": "NCT07660666",
      "title": "Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Electronic Health Record Review",
          "type": "OTHER"
        },
        {
          "name": "Internet-Based Intervention",
          "type": "OTHER"
        },
        {
          "name": "Patient Navigation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-11-01",
      "completion_date": "2029-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-11-18T19:47:21.490Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07660666"
    },
    {
      "nct_id": "NCT04038619",
      "title": "Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colitis",
        "Diarrhea",
        "Malignant Genitourinary System Neoplasm",
        "Melanoma",
        "Lung Cancer",
        "Ovarian Cancer",
        "Uterine Cancer",
        "Breast Cancer",
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "Fecal Microbiota Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Loperamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2021-02-01",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-11-18T19:47:21.490Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04038619"
    }
  ]
}